EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SGLT2 Inhibitors as a Novel Therapeutic Strategy in SIADH-Induced Hyponatraemia: Emerging Evidence and Clinical Implications

Neena Kamran iD, Misbah Mohammad

Journal of Clinical Medicine · 10.03.2026 · 15 (6) · 2119

DOI: 10.3390/jcm15062119 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 10.03.2026. Verfasst von Neena Kamran und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Mid Yorkshire Teaching NHS Trust, Wakefield WF1 4DG, UK. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a leading cause of euvolaemic hyponatraemia and remains challenging to manage due to limitations of existing therapies, including poor adherence to fluid restriction and safety concerns associated with vasopressin receptor antagonists and demeclocycline. Recent mechanistic and clinical evidence suggests that sodium–glucose cotransporter-2 (SGLT2) inhibitors may offer a novel therapeutic approach by promoting osmotic diuresis and increasing electrolyte-free water clearance. This narrative review synthesises current pathophysiological understanding and emerging clinical evidence regarding the role of SGLT2 inhibitors in SIADH-related hyponatraemia. We examine how their proximal tubular mechanism differs from conventional therapies such as loop diuretics, vaptans, and salt supplementation, and evaluate evidence from recent randomised and crossover trials demonstrating improved serum sodium and enhanced water excretion with empagliflozin and dapagliflozin. SGLT2 inhibitors represent a physiologically rational and potentially safer alternative in selected patients with SIADH, particularly where fluid restriction is poorly tolerated or ineffective. Although further large-scale studies are required to define their optimal positioning within treatment algorithms, current evidence supports their potential role as an emerging therapeutic option in SIADH management.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitorsSIADHdapagliflozinelectrolyte disordersempagliflozinhyponatraemiavasopressin

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Mid Yorkshire Teaching NHS Trust, Wakefield WF1 4DG, UK.

ORCID-Profile: Neena Kamran

Zitieren

APA

Kamran, N., & Mohammad, M. (2026). SGLT2 Inhibitors as a Novel Therapeutic Strategy in SIADH-Induced Hyponatraemia: Emerging Evidence and Clinical Implications. Journal of Clinical Medicine, 15(6), 2119. https://doi.org/10.3390/jcm15062119

Vancouver

Kamran N, Mohammad M. SGLT2 Inhibitors as a Novel Therapeutic Strategy in SIADH-Induced Hyponatraemia: Emerging Evidence and Clinical Implications. Journal of Clinical Medicine. 2026;15(6):2119. doi:10.3390/jcm15062119

BibTeX
@article{Kamran2026,
  author = {Kamran, Neena and Mohammad, Misbah},
  title = {SGLT2 Inhibitors as a Novel Therapeutic Strategy in SIADH-Induced Hyponatraemia: Emerging Evidence and Clinical Implications},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {6},
  pages = {2119},
  doi = {10.3390/jcm15062119}
}
Kostenlos starten →